High-Density Lipoprotein Infusions - 31/03/18
Résumé |
High-density lipoproteins (HDLs) have presented an attractive target for development of new therapies for cardiovascular prevention on the basis of epidemiology and preclinical studies demonstrating their protective properties. Development of HDL mimetics provides an opportunity to administer functional HDL. However, clinical trials have produced variable results, with no evidence to date that they reduce cardiovascular events. This article reviews development programs of HDL mimetics.
Le texte complet de cet article est disponible en PDF.Keywords : High-density lipoproteins, Lipids, Cardiovascular risk, Atherosclerosis
Plan
| Disclosure: Nicholls disclosures are research support from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and a consultant for AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. Other authors have no disclosures. |
Vol 36 - N° 2
P. 311-315 - mai 2018 Retour au numéro
Article précédent
- Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk
- Philip J. Barter, Kerry-Anne Rye
- High-Density Lipoproteins : Effects on Vascular Function and Role in the Immune Response
- Arash Haghikia, Ulf Landmesser
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?